In search of a molecular classifier for pancreatic cancers vulnerable to MAPK pathway blockade via MEK inhibition which is not dependent on a complex gene expression signature, our prior work identified the KRAS mutational isoform G12R as a candidate [16]. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.